Celsion Corporation, a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 50,000 shares of Series A convertible redeemable preferred stock and 50,000 shares of Series B convertible redeemable preferred stock.
January 10, 2022
· 6 min read